CNS Pharmaceuticals, Inc. (CNSP): Nasdaq/NYSE listing notice — CNS Pharma receives Nasdaq delisting notice for failure to meet $2.5M equity requirement

CNS Pharmaceuticals, Inc.

Nasdaq notified CNS Pharma on Aug 17, 2023 of non-compliance with $2.5M stockholders' equity minimum (Rule 5550(b)(1)).
Company also does not meet alternatives of market value of listed securities or net income from continuing operations.
No immediate delisting; company has 45 calendar days to submit a plan. Nasdaq may grant up to 180-day extension if plan accepted.
If plan rejected, company may appeal to Nasdaq Hearings Panel; no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CNS Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

August 17, 2023, CNS Pharmaceuticals, Inc. (the “Company”) received a letter (the “Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in stockholders’ equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Letter does

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-005908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.